ADMA · ADMA Biologics Inc.
AI read · Good for ADMA
The AI's read
More doctors are choosing ASCENIV, and ADMA said demand stayed strong into the fourth quarter. A study of 127 patients also found fewer infections and less related care after treatment. BIVIGAM faced competitor price cuts, and its sales declined. Management saw demand stabilizing and chose to protect profit margins instead of discounting heavily. ASCENIV demand drove profit growth, so the BIVIGAM decline does not outweigh the stronger business update.